Lesson plan
halometasone
Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other regions such as China, Hong Kong, Turkey, Israel, South Africa and India. It has been used to treat chronic psoriasis vulgaris and non-infected acute eczematous dermatoses (eczema). One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well tolerated, with no systemic adverse effects reported.
Article summary
Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other regions such as China, Hong Kong, Turkey, Israel, South Africa and India. It has been used to treat chronic psoriasis vulgaris and non-infected acute eczematous dermatoses (eczema). One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well tolerated, with no systemic adverse effects reported.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.